Previous 10 | Next 10 |
ImmunityBio ([[IBRX]] +3.4%) announces two South African studies to examine the potential of hAd5 T-cell-based COVID-19 vaccine candidate to provide extended protection for subjects with prior COVID-19 vaccinations or infections.The first study will involve 40 subjects previously infected wit...
ImmunityBio ([[IBRX]] +1.7%) talks up upcoming poster presentation highlighting its chemotherapy free regimen of interleukin-15 (IL-15) superagonist anktiva in patients who had relapsed from checkpoint inhibitors, at the 2021 American Society of Clinical Oncology ((ASCO)) Annual Meeting,...
Chemotherapy free regimen (with NK and T cell activation via Anktiva) in patients across multiple tumor types who failed checkpoint inhibitor therapy 140 patients accrued to date in this basket trial of checkpoint failures in lung cancer, melanoma, urothelial, head & neck, gas...
3 Top Biotech Stocks To Watch In The Stock Market Today Biotech stocks remain on many investors’ radar and for good reasons. Biotech companies are usually more insulated from global events such as the ongoing COVID-19 pandemic and economic uncertainty. Simply put, top biote...
ImmunityBio (IBRX) has received FDA authorization to conduct a Phase 1 study to evaluate the safety and preliminary efficacy of its m-ceNK platform combined with its IL-15 superagonist Anktiva (N-803) in subjects with locally advanced or metastatic solid tumors.These NK cells retrieved from t...
The first-in-class, memory cytokine-enriched Natural Killer (m-ceNK™) cells are the patient’s own NK cells that have been enriched with cytokines, including ImmunityBio’s IL-15 superagonist Anktiva (N-803) The resulting cryopreserved m-ceNK cells have an enhan...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips During the past year, there was a justifiable obsession with the race to a vaccine for the novel coronavirus. And the companies in that race were making headlines constantly, with prices for longshots soaring and even the b...
ImmunityBio (IBRX) announces results from its Phase 1 study evaluating Anktiva (N-803), its IL-15 superagonist, in combination with Rituxan (rituximab) in certain patients with indolent non-Hodgkin lymphoma, a rare form of blood cancer.The study enrolled patients with iNHL (follicular ly...
Durable complete response achieved in 7 of 9 (78%) CD20 sensitive patients who failed Rituxan® therapy in Phase 1 liquid tumor trial Of those patients who responded to the combination therapy of Anktiva™ plus Rituxan, 7 out of 7 (100%) achieved a complete response ...
The U.S. Military HIV Research Program has launched a Phase 2 clinical trial in Thailand to evaluate ImmunityBio’s (IBRX) interleukin-15 (IL-15) superagonist Anktiva (also called N-803) in combination with antiretroviral therapy ((ART)) during acute HIV infection as an experimental the...
News, Short Squeeze, Breakout and More Instantly...
2024-07-27 01:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into ImmunityBio, Inc. (NasdaqGS: IBRX). On May 11, 2023, the Company disclosed that it had receiv...